Literature DB >> 26675554

Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.

Avirup Chowdhury1, Martin J Brodie2.   

Abstract

PURPOSE: Juvenile myoclonic epilepsy (JME) is one of the most frequently diagnosed of the idiopathic generalised epilepsy syndromes, but long term outcome data still remain sparse.
METHODS: A retrospective audit was undertaken in 186 patients (male: n=78; female: n=108) diagnosed with JME at the Epilepsy Unit at the Western Infirmary in Glasgow, Scotland between July 1981 and July 2012. Median age at treatment start was 16 years (range 13-44), with median follow-up of 14 years (range 2-32).
RESULTS: Overall, 171 patients (92%) achieved remission with antiepileptic drug (AED) treatment (median 9.5 years; range 1-31). After discontinuing treatment in 28 patients, only 11 remained seizure-free off medication. Fifteen patients (8%) continued to have seizures despite having tried up to 8 AED regimens: (5 male, 10 female), 7 of whom had psychiatric comorbidities. AEDs most commonly prescribed included sodium valproate (VPA; n=142), lamotrigine (LTG; n=66) and levetiracetam (LEV; n=22). More male patients than female attained remission with their first or second AED schedule (88% versus 56%). More male patients (44%) received VPA than female (31%) overall. Fewer male patients than female received LTG (26% versus 74%) and LEV (22% versus 78%). Of the monotherapies, remission was achieved using VPA (n=74; 52%), LTG (n=21; 32%) and LEV (n=12, 55%). A total of 76 (25%) of AED schedules resulted in intolerable side-effects, including 29 with VPA, 12 with LTG and 4 with LEV.
CONCLUSION: Overall, JME showed a high rate of seizure freedom with AED treatment. VPA appeared to be the most effective AED. Women tended to have a worse outcome than men, since they were increasingly less likely to receive VPA. Patients with psychiatric comorbidities also had a poorer prognosis.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiepileptic drugs; Efficacy; Juvenile myoclonic epilepsy; Outcomes; Psychiatric comorbidities; Side effects

Mesh:

Substances:

Year:  2015        PMID: 26675554     DOI: 10.1016/j.eplepsyres.2015.11.012

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  7 in total

Review 1.  Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults.

Authors:  Linda J Stephen; Martin J Brodie
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

Review 2.  Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.

Authors:  Anna Serafini; Elizabeth Gerard; Pierre Genton; Arielle Crespel; Philippe Gelisse
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

3.  Practice Current: When do you stop antiepileptic drugs in patients with genetic generalized epilepsies and in those with focal epilepsies?

Authors:  Luca Bartolini
Journal:  Neurol Clin Pract       Date:  2016-12

4.  Seizure control in mono- and combination therapy in a cohort of patients with Idiopathic Generalized Epilepsy.

Authors:  Leonardo Zumerkorn Pipek; Henrique Zumerkorn Pipek; Luiz Henrique Martins Castro
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

5.  Uncertainties from a worldwide survey on antiepileptic drug withdrawal after seizure remission.

Authors:  Luca Bartolini; Shahram Majidi; Mohamad Z Koubeissi
Journal:  Neurol Clin Pract       Date:  2018-04

6.  Clinical features and treatment outcomes of Juvenile myoclonic epilepsy patients.

Authors:  Yingying Zhang; Jiani Chen; Jiechuan Ren; Wenyu Liu; Tianhua Yang; Dong Zhou
Journal:  Epilepsia Open       Date:  2019-04-19

7.  Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy.

Authors:  Katri Silvennoinen; Nikola de Lange; Sara Zagaglia; Simona Balestrini; Ganna Androsova; Merel Wassenaar; Pauls Auce; Andreja Avbersek; Felicitas Becker; Bianca Berghuis; Ellen Campbell; Antonietta Coppola; Ben Francis; Stefan Wolking; Gianpiero L Cavalleri; John Craig; Norman Delanty; Michael R Johnson; Bobby P C Koeleman; Wolfram S Kunz; Holger Lerche; Anthony G Marson; Terence J O'Brien; Josemir W Sander; Graeme J Sills; Pasquale Striano; Federico Zara; Job van der Palen; Roland Krause; Chantal Depondt; Sanjay M Sisodiya
Journal:  Epilepsia Open       Date:  2019-07-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.